Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.
Carlos M GriloJanet A LydeckerAnia M JastreboffBrian PittmanSherry A McKeePublished in: Obesity (Silver Spring, Md.) (2023)
Naltrexone/bupropion did not demonstrate effectiveness for reducing binge eating relative to placebo but showed effectiveness for weight reduction in patients with BED. Obesity status did not predict or moderate medication outcomes.
Keyphrases
- double blind
- weight loss
- placebo controlled
- randomized controlled trial
- systematic review
- clinical trial
- weight gain
- physical activity
- study protocol
- metabolic syndrome
- insulin resistance
- phase iii
- type diabetes
- body mass index
- healthcare
- alcohol use disorder
- high intensity
- phase ii
- emergency department
- glycemic control
- open label
- adverse drug
- anorexia nervosa